You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK)附屬就達百納培南、Plazomicin與上藥新亞達獨家授權許可
阿思達克 06-16 12:14
四環醫藥(00460.HK)表示,旗下非全資附屬軒竹生物與上海醫藥非全資附屬上藥新亞訂立許可合約,以在大中華區就軒竹生物的兩款抗感染新藥產品百納培南及Plazomicin原料藥和製劑與上藥新亞達成獨家授權許可。 根據授權許可合約的條款,上藥新亞將獲得上述兩款產品原料藥和製劑在大中華區的獨家權益,包括分許可、研發、生產、商業化等在內的一切權益,並成為兩款產品在大中華區的上市許可持有人(MAH)。 公司指,軒竹生物將獲得2,100萬元人民幣(下同)的預付款,並有權收取最高不超過4.19億元的里程碑付款,以及最高可達兩位數的分級特許銷售分成。 百納培南是軒竹生物自主研發的1.1類新型碳青黴烯類抗生素新藥,擬用於治療複雜性尿路感染和社區獲得性肺炎。 Plazomicin是由美國Achaogen公司開發的新一代半合成氨基糖(甘)類抗生素,主要通過與細菌核糖體30S亞基結合,產生抑菌作用,開發用於治療多藥耐藥(MDR)革蘭氏陰性菌腸桿菌科細菌導致的嚴重感染。2019年12月軒竹生物已收購該產品在大中華地區的一切所有權益及相關知識產權。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account